Primary thrombotic microangiopathy |
TTP |
Congenital TTP |
|
Acquired TTP |
|
HUS |
STEC-HUS |
|
Atypical HUS |
Genetic mutations in complement regulatory proteins (e.g., CFH, CFI, MCP, C3, CFB, THBD); (13)– (15) anti-CFH autoantibodies (16)
|
Secondary thrombotic microangiopathy |
Malignant hypertension |
|
Pregnancy-associated thrombotic microangiopathy, preeclampsia/eclampsia, HELLP |
|
Drugs and toxins (e.g., calcineurin inhibitors, quinine, ticlopidine) |
|
Infections (e.g., influenza, HIV, Epstein–Barr virus, parvovirus) |
|
Cancer |
|
Autoimmune disease (e.g., systemic lupus erythematosus) |
|
Transplantation (e.g., solid organ, bone marrow) |
Consider graft versus host disease, graft rejection, conditioning regimen, antirejection therapy (23)
|
Disseminated intravascular coagulation |
|
Metabolic (e.g., cobalamin C deficiency) |
|